| Property | Value |
|---|
|
?:abstract
|
-
Beta cell dysfunction is suggested in patients with COVID-19 infections Poor glycemic control in ICU is associated with poor patient outcomes This is a single center, retrospective analysis of 562 patients in an intensive care unit from 1 March to 30 April 2020 We review the time in range (70–150 mg/dL) spent by critically ill COVID-19 patients and non-COVID-19 patients, along with the daily insulin use Ninety-three in the COVID-19 cohort and 469 in the non-COVID-19 cohort were compared for percentage of blood glucose TIR (70–150 mg/dL) and average daily insulin use The COVID-19 cohort spent significantly less TIR (70–150 mg/dL) compared to the non-COVID-19 cohort (44 4% vs 68 5%) Daily average insulin use in the COVID-19 cohort was higher (8 37 units versus 6 17 units) ICU COVID-19 patients spent less time in range (70–150 mg/dL) and required higher daily insulin dose A higher requirement for ventilator and days on ventilator was associated with a lower TIR Mortality was lower for COVID-19 patients who achieved a higher TIR
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
Journal_of_Clinical_Medicine
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Maintaining Blood Glucose Levels in Range (70–150 mg/dL) is Difficult in COVID-19 Compared to Non-COVID-19 ICU Patients—A Retrospective Analysis
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}